↓ Skip to main content
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Readers on

mendeley
464 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia: The LAPLACE-2 Randomized Clinical Trial
Published in
JAMA: Journal of the American Medical Association, May 2014
DOI 10.1001/jama.2014.4030
Pubmed ID
Authors
Abstract

In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 27 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 464 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
United States 3 <1%
Netherlands 3 <1%
Russia 1 <1%
Mexico 1 <1%
Hong Kong 1 <1%
United Kingdom 1 <1%
Austria 1 <1%
Unknown 453 98%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 56 12%
Other 55 12%
Student > Bachelor 41 9%
Student > Ph. D. Student 41 9%
Student > Master 39 8%
Other 84 18%
Unknown 148 32%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 170 37%
Pharmacology, Toxicology and Pharmaceutical Science 49 11%
Agricultural and Biological Sciences 25 5%
Biochemistry, Genetics and Molecular Biology 10 2%
Economics, Econometrics and Finance 7 2%
Other 35 8%
Unknown 168 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 130. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 April 2026.
All research outputs
#406,058
of 34,457,357 outputs
Outputs from JAMA: Journal of the American Medical Association
#4,650
of 42,333 outputs
Outputs of similar age
#2,836
of 275,178 outputs
Outputs of similar age from JAMA: Journal of the American Medical Association
#48
of 397 outputs
Altmetric has tracked 34,457,357 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 42,333 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 73.1. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,178 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 397 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.